Neurocrine Biosciences Announces Publication Of Positive Results From Kinect 3 Phase III Study Of INGREZZA TM (Valbenazine) For The Treatment Of Tardive Dyskinesia Post author:Sam Post published:March 20, 2017 Post category:BioPharma Life Sciences Jobs … Source: BioSpace You Might Also Like A Look at Gilead's Possible New Drug Strategy May 30, 2017 Biogen and AbbVie Voluntarily Pull Multiple Sclerosis Drug Off the Market March 1, 2018 Most-Wanted Life Sciences Employers in Genetown January 21, 2018